The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Merging old and new perspectives on nicotinic acetylcholine receptors
Open accessAbstract
This review covers history underlying the discovery of the molecular mediators of nicotine's effects in the brain and the diversity of the nicotinic acetylcholine receptor (nAChR) subtypes. Models are presented for both their structure and their function as mediators of signal transduction, with special consideration of the differences between the two main subtypes: heteromeric receptors, which are specialized for rapid electrochemical signal transduction, and homomeric α7 receptors, which have come to be implicated in both ionotropic and metabotropic signaling. The review presents perspectives on the pharmacology and therapeutic targeting of nAChRs for the treatment of nicotine dependence or disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., et al. (2003) · Nature · doi:10.1038/nature01339 · Cited by 3,228
Long-term potentiation of excitatory inputs to brain reward areas by nicotine
Mansvelder, H. D., & McGehee, D. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00042-8 · Cited by 720
Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas
Mansvelder, H. D., Keath, J. R., & McGehee, D. S. (2002) · Neuron · doi:10.1016/s0896-6273(02)00625-6 · Cited by 701 · cited 1×
“The functional significance of this difference has been highlighted in studies of the dopaminergic outflow from the ventral tegmentum, where a7 and non-a7 receptors play contrasting neuromodulatory roles [68].”
BackgroundAcetylcholine Receptor: An Allosteric Protein
Changeux, J.-P., Devillers-Thiéry, A., & Chemouilli, P. (1984) · Science · doi:10.1126/science.6382611 · Cited by 623
Structural and functional diversity of native brain neuronal nicotinic receptors
Gotti, C., Clementi, F., Fornari, A., Gaimarri, A., Guiducci, S., Manfredi, I., Moretti, M., Pedrazzi, P., Pucci, L., & Zoli, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.024 · Cited by 469
PICCIOTTO, M., ADDY, N., MINEUR, Y., & BRUNZELL, D. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.12.005 · Cited by 460 · cited 1×
“debate [47], it is generally believed that the transient phase of receptor activation achieved with cigarette delivery of nicotine is important for the immediate reinforcing properties of the drug and that this reinforcement is associated with a transient increase in mesolimbic DA release.”
BackgroundAlternate stoichiometries of α4β2 nicotinic acetylcholine receptors
Nelson, M. E., Kuryatov, A., Choi, C. H., Zhou, Y., & Lindstrom, J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.332 · Cited by 422
The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum
Grady, S. R., Salminen, O., Laverty, D. C., Whiteaker, P., McIntosh, J. M., Collins, A. C., & Marks, M. J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.032 · Cited by 252
Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis
Papke, R. L., & Porter Papke, J. K. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704833 · Cited by 249
Self-citationPicciotto, M. R., Caldarone, B. J., Brunzell, D. H., Zachariou, V., Stevens, T. R., & King, S. L. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00161-9 · Cited by 221
Roles of Accessory Subunits in α4β2* Nicotinic Receptors
Kuryatov, A., Onksen, J., & Lindstrom, J. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.046789 · Cited by 195
Drug targets for cognitive enhancement in neuropsychiatric disorders.
Wallace, T. L., Ballard, T. M., Pouzet, B., Riedel, W. J., & Wettstein, J. G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.022 · Cited by 127
Zwart, R., Carbone, A. L., Moroni, M., Bermudez, I., Mogg, A. J., Folly, E. A., Broad, L. M., Williams, A. C., Zhang, D., Ding, C., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.045104 · Cited by 111 · cited 1×
“An agent which selectively activates one receptor subtype may bind to other receptors as well and act as a competitive antagonist [85] or desensitizing agent [86] at those”
BackgroundCytisine-based nicotinic partial agonists as novel antidepressant compounds
Mineur, Y. S., Eibl, C., Young, G., Kochevar, C., Papke, R. L., Gündisch, D., & Picciotto, M. R. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.149609 · Cited by 75 · cited 1×
“Some drugs need help to cross the blood brain barrier [80]; others are most probative only if delivered to specific target nuclei within the brain.”
BackgroundSelf-citationPollock, V. V., Pastoor, T., Katnik, C., Cuevas, J., & Wecker, L. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.11.032 · Cited by 31
Cited by
Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine
Dani, J. A. (2015) · International Review of Neurobiology · doi:10.1016/bs.irn.2015.07.001 · Cited by 309
Conotoxins: Chemistry and Biology
Jin, A.-H., Muttenthaler, M., Dutertre, S., Himaya, S. W. A., Kaas, Q., Craik, D. J., Lewis, R. J., & Alewood, P. F. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00207 · Cited by 261
Smucny, J., Stevens, K. E., Olincy, A., & Tregellas, J. R. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.77 · Cited by 28
Bristow, L. J., Easton, A. E., Li, Y.-W., Sivarao, D. V., Lidge, R., Jones, K. M., Post-Munson, D., Daly, C., Lodge, N. J., Gallagher, L., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159996 · Cited by 30
Metadata
- Authors
- Papke, R. L.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 89
- Issue
- 1
- Pages
- 1-11
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2128845098
- Cited by
- 180
- References
- 15
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.